▲定档11月!第二届ADC&新型抗体药物工艺控峰会重磅来袭!当地时间11月7日,Metsera宣布已与辉瑞签订修订后的合并协议,辉瑞将以每股最高86.25美元的价格收购这家备受追捧的减肥药研发企业。这场持续近三个月的竞购战堪称医药界年度“商战大片”,两家制药巨头的较量从价格战延伸到法律战,最终在监管风险这一变量上分出胜负。Metsera董事会直言,尽管诺和诺德的报价颇具吸引力,但其交易方案存在“...
Source Link▲定档11月!第二届ADC&新型抗体药物工艺控峰会重磅来袭!当地时间11月7日,Metsera宣布已与辉瑞签订修订后的合并协议,辉瑞将以每股最高86.25美元的价格收购这家备受追捧的减肥药研发企业。这场持续近三个月的竞购战堪称医药界年度“商战大片”,两家制药巨头的较量从价格战延伸到法律战,最终在监管风险这一变量上分出胜负。Metsera董事会直言,尽管诺和诺德的报价颇具吸引力,但其交易方案存在“...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.